Keryx Biopharmaceuticals Inc fka KERX

[jammyjames]

"These include continued growth in the U.S. dialysis market, acceptance and assignment of a target review date for the supplemental new drug application submitted in January to the U.S. FDA to expand the indication of Auryxia for the treatment of iron deficiency anemia (IDA) in adults with non-dialysis dependent chronic kidney disease, and the subsequent approval and launch in late 2017"

I guess this means they've applied for fast track status as they should be getting their 74 day letter soon